Financials
Financial year 2025
Roval Pharma from Bever, company number BE0553481307, closed financial year 2025 with a result of € 77,986 after tax. For that financial year Roval Pharma recorded a gross margin of € 106,990 and equity of € 709,849. Compared with financial year 2024, the result moved from € 93,118 to € 77,986. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ 709,849
▲ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 77,986
▼ 16% vs 2024
Profit after tax over the fiscal year.
€ 10,669
▼ 20% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 691,299.
People and assets in 2025
€ 12,801
▲ 156% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 5,532
€ 1,994 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 3,430
▲ € 2,708 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 65,621
▲ 43% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 95,932 | € 89,502 | € 133,798 | € 106,990 | ▼ 20% |
| Profit after taxes | € 55,603 | € 15,887 | € 93,118 | € 77,986 | ▼ 16% |
| Equity | € 522,857 | € 538,744 | € 631,862 | € 709,849 | ▲ 12% |
| Total debts | € 170,890 | € 69,687 | € 46,599 | € 74,583 | ▲ 60% |
| Cash | € 4,492 | € 12,570 | € 13,354 | € 10,669 | ▼ 20% |
| Retained profit | € 504,307 | € 520,194 | € 613,312 | € 691,299 | ▲ 13% |
| Bank debt | € 4,035 | € 0 | € 0 | € 5,532 | |
| Balance sheet total | € 693,747 | € 608,431 | € 678,462 | € 784,432 | ▲ 16% |
Key figures of Roval Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Roval Pharma?
What happened at Roval Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 77,986 (▼ 16% vs 2024). filed late Source: NBB ↗
- Start of the company according to the CBE. KBO
In short
From € 55,603 profit in 2022 to € 77,986 profit in 2025.
Paid € 102,487 in corporate taxes since 2022.
Best year ever: 2024, with € 93,118 profit.
Management
Behind Roval Pharma is Valentyna KONOSHUK. It owns 85.3% of AB BEAUTY itself.
Directors
According to the 2025 annual accounts
Valentyna KONOSHUK
Director
Establishments
Establishment units
Physical locations of this company
Akrenbos 51
1547 Bever
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0553.481.307
- VAT number
- BE 0553.481.307
- Registered office
- Akrenbos 51, 1547 Bever
- Names & denominations
- Roval Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 May 2014
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige zakelijke dienstverlening, neg